Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis

Annals of the Rheumatic Diseases

Volumn 76, Issue 9, 2017, Pages 1550-1558

  Mease, Philip J ^a   Gottlieb, Alice B ^b   Van Der Heijde, Désireé ^c   Fitzgerald, Oliver ^d   Johnsen, Alyssa ^e   Nys, Marleen ^e   Banerjee, Subhashis ^e   Gladman, Dafna D ^f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^e BRISTOL MYERS SQUIBB   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

DMARDs (biologic); Psoriatic arthritis; T cells; Treatment

Indexed keywords

ABATACEPT; CORTICOSTEROID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT;

ADULT; AMERICAN COLLEGE OF RHEUMATOLOGY CRITERIA; ARTICLE; AUTOIMMUNE DISEASE; BRONCHITIS; CONTROLLED STUDY; DACTYLITIS; DAS28; DERMATOLOGY LIFE QUALITY INDEX; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTHESITIS; FEMALE; FUNCTIONAL STATUS ASSESSMENT; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCULOSKELETAL DISEASE ASSESSMENT; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; PSORIATIC ARTHRITIS DISEASE ACTIVITY SCORE; PSORIATIC DISEASE ACTIVITY INDEX; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SHORT FORM 36; UPPER RESPIRATORY TRACT INFECTION; ARTHRITIS, PSORIATIC; CLINICAL TRIAL; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; PATHOPHYSIOLOGY; PNEUMONIA, PNEUMOCYSTIS; TREATMENT OUTCOME;

ABATACEPT; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCYSTIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 85021745806     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210724     Document Type: Article

References (42)

1. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14-ii17.
2. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2013;69:729-35.
3. Lemos LL, de Oliveira Costa J, Almeida AM, et al. Treatment of psoriatic arthritis with anti-TNF agents: A systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int 2014;34:1345-60.
4. R amiro S, Smolen JS, Landewé R, et al. Pharmacological treatment of psoriatic arthritis: A systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2016;75:490-8.
5. Ungprasert P, Thongprayoon C, Davis JM. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: A meta-analysis. Clin Rheumatol 2016;35:1795-803.
6. Fitzgerald O, Winchester R. Psoriatic arthritis: From pathogenesis to therapy. Arthritis Res Ther 2009;11:214.
7. Cutolo M, Nadler SG. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev 2013;12:758-67.
8. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-9.
9. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
10. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med 2006;144:865-76.
11. R uperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91.
12. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: A phase III, multi-centre, randomised, double-blind, placebocontrolled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
13. Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after antitumour necrosis factor therapy or were directly switched to abatacept: The ARRIVE trial. Ann Rheum Dis 2009;68:1708-14.
14. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7.
15. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63:939-48.
16. Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011;63:2854-64.
17. T aylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
18. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
19. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint disease activity score (DAS28) and European League against Rheumatism response criteria based on C-reactive protein against disease progression in patients with Rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60.
20. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008;59:686-91.
21. Helliwell PS, Firth J, Ibrahim GH, et al. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 2005;32:1745-50.
22. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: The health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
23. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
24. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment. Ann Rheum Dis 2010;69:48-53.
25. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011;70:272-7.
26. Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986-91.
27. Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69:1441-7.
28. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
29. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
30. van der Heijde D, Sharp J, Wassenberg S, et al. Psoriatic arthritis imaging: A review of scoring methods. Ann Rheum Dis 2005;64(Suppl 2):ii61-ii64.
31. Benham H, Norris P, Goodall J, et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther 2013;15:R136.
32. Menon B, Gullick NJ, Walter GJ, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol 2014;66:1272-81.
33. Scarsi M, Zanotti C, Chiarini M, et al. Reduction of peripheral blood T cells producing IFN-and IL-17 after therapy with abatacept for rheumatoid arthritis. Clin Exp Rheumatol 2014;32:204-10.
34. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, doubleblind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27.
35. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010;340:c147.
36. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014;73:1020-6.
37. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;386:1137-46.
38. R itchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, Ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebocontrolled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990-9.
39. Kavanaugh A, McInnes IB, Mease PJ, et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: Results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol 2016;43:1713-7.
40. Johnsson HJ, McInnes IB. Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis. Clin Exp Rheumatol 2015;33:S115-S118.
41. Schiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology 2013;52:986-97.
42. Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev 2012;25:297-317.